Development of the M184V Mutation in HIV-1 Infection and Subsequent Treatment Outcomes
DOI:
https://doi.org/10.17140/HARTOJ-2-114Keywords:
HIV, Drug resistance, Lamivudine, Antiretroviral therapy, HIV drug resistanceAbstract
Objective: The purpose of this study was to describe the occurrence of the M184V mutation in a single clinic setting over a period of 10 years. We examined the combination Antiretroviral Therapy (cART) being taken at the time of first identification of the M184V mutation as well as Second Line Regimens (SLR) started immediately after the documentation of M184V. SLR were evaluated for frequency and time to Virologic Suppression (VS) as well as frequency and time to subsequent Virologic Failure (VF).
Design: This was a retrospective cohort study of all Human Immunodeficiency Virus (HIV) infected patients receiving care at the Washington University School of Medicine Infectious Disease Clinic in St. Louis, MO, USA between January 2001 and June 2010.
Methods: Prevalence of the M184V mutation, ART regimen leading to M184V acquisition, and outcomes of SLR in patients with M184V (as measured by time to initial VS and subsequent VF on SLR) were analyzed in a retrospective cohort study of all HIV-infected persons receiving care at a university clinic.
Conclusions: M184V mutation developed in 9% of patients in a mean of 575 days with no significant differences between ART regimens. Following initiation of an SLR, the majority of patients achieved VS in approximately 179 days irrespective of the regimen. The addition of 3TC/FTC did not significantly affect VS. Although numbers were small, 100% of patients on two fully active non-NRTI-backbone-based regimens attained VS. Approximately half of all patients subsequently failed on SLR, regardless of regimen used, suggesting that the development of M184V is a marker of noncompliance to therapy.
References
Aberg JA, Kaplan JE, Libman H, et al. Primary care guide-lines for the management of persons infected with human im-munodeficiency virus: 2009 update by the HIV medicine Asso-ciation of the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49(5): 651-681. doi: 10.1086/605292
Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scien-tific principles and clinical applications. Drugs. 2012; 72(9): e1- e25. doi: 10.2165/11633630-000000000-00000
Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006; 3(9): e356. doi: 10.1371/journal.pmed.0030356
Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 2005; 19(5): 487-494.
Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008; 47(5): 712-722. doi: 10.1086/590943
Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line anti-retroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007; 44(3): 447-452. doi: 10.1086/510745
Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Ly-agoba F, et al. High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis. 2014; 58(7): 1023-1026. doi: 10.1093/cid/cit933
Puthanakit T, Jourdain G, Suntarattiwong P, et al. High vi-rologic response rate after second-line boosted protease inhib-itor-based antiretroviral therapy regimens in children from a resource limited setting. AIDS Res Ther. 2012; 9(1): 20. doi: 10.1186/1742-6405-9-20
Scherrer AU, Boni J, Yerly S, et al. Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and pro-tease inhibitors (PIs) by boosted PI containing regimens. PLoS One. 2012; 7(11): e50307. doi: 10.1371/journal.pone.0050307
Johnston V, Cohen K, Wiesner L, et al. Viral suppression following switch to second-line antiretroviral therapy: associa-tions with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014; 209(5): 711-720. doi: 10.1093/infdis/jit411
Maserati R, De SA, Uglietti A, et al. Emerging mutations at virological failure of HAART combinations containing tenofo-vir and lamivudine or emtricitabine. AIDS. 2010; 24(7): 1013- 1018. doi: 10.1097/QAD.0b013e328336e962
Allavena C, Ferre V, Brunet-Francois C, et al. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-spar-ing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005; 39(3): 300-306.
Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008; 358(20): 2095-2106. doi: 10.1056/NEJMoa074609
Kozal MJ, Lupo S, DeJesus E, et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPAR-TAN study results. HIV Clin Trials. 2012; 13(3): 119-130. doi: 10.1310/hct1303-119
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in HIV/AIDS Research and Treatment (HRT) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
